The European Foundation for the Study of Diabetes (EFSD) and the Novo Nordisk Foundation Precision Diabetes Medicine Award recognises innovative research from both clinicians and basic scientists in precision diabetes medicine who are able to see into and seek solutions for the future. The recipients will describe novel precision profiled projects that will benefit people with diabetes, and investigators may already have an established track record within the area. The awarded projects are expected to accelerate important fields of translational research and to improve the speed of innovation implementation in diabetes care.
The Award will be open for applications 3 years running, celebrating the discovery of insulin in 1921, its first use of humans in 1922 and its first Nobel Prize in 1923.
The Programme comprises three Awards annually: a winner and two runners-up. The winning project receives DKK 2 million and the runners-up DKK 0.5 million each to support research over 3 years.
The recipients will be invited to submit an article from their perspective to Diabetologia and will be invited to give an award lecture at the Future of Precision Medicine Symposium 2023, which will be held in November 2023 at the Novo Nordisk Foundation, Copenhagen.
The applications will be reviewed by a specialised and independent ad hoc committee organised by the EFSD, and the Novo Nordisk Foundation donates the money accompanying the Award.
The call for applications in 2023 is now open. The deadline for applications is 15 May 2023 and more information about eligibility is available on the EFSD website.
Professor Thomas Pieber’s prize lecture and other talks from the Future of Precision Medicine Symposium 2021 can be viewed here.